Booth L05 for Clinically Backed NMN & Liposomal VC

Overview

EFFEPHARM LTD

This year’s Vitafoods Asia, EffePharm will showcase innovative anti-aging solutions, featuring Uthever® NMN, the world’s first large-scale, human clinically-proven NMN brand.

Also discover clinically-backed ingredient delivery technologies for enhanced bioavailability and functionality, featuring LipoAvail® liposomal VC and more. LipoAvail® vitamin C offers enhanced health benefits such as better absorption, immune support, skin radiance, and antioxidant protection—all backed by scientific data.

Download the NMN Whitepaper to learn more.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Related Topics

IngredientsHealth

Latest Content

Related Resources

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

Paid for by Effepharm Ltd

White Paper

On 11th May 2026, EFSA officially published a positive scientific opinion on EffePharm’s β-NMN as a novel food. This is the first-ever EU official safety endorsement for NMN. UTHEVER® is the 1st NMN ingredient brand to receive EFSA’s positive opinion.

Uthever® NMN: Novel Food Approval Nearing Final Stage

Uthever® NMN: Novel Food Approval Nearing Final Stage

Paid for by Effepharm Ltd

White Paper

One Step Away from EU Market Compliance for NMN. The official positive opinion of Novel Food is expected to be published shortly, which means Uthever® NMN will be the first compliant ingredient.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.